Last reviewed · How we verify
Asthma reliever and controller
Bronchodilator
Bronchodilator Used for Asthma.
At a glance
| Generic name | Asthma reliever and controller |
|---|---|
| Sponsor | Ivan Sofian Wibowo |
| Drug class | Bronchodilator |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 1 |
Mechanism of action
Acts by relaxing bronchial smooth muscles to improve airflow in the lungs.
Approved indications
- Asthma
Common side effects
- Tremor
- Headache
- Nausea
Key clinical trials
- Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion) (PHASE3)
- Individualizing Treatment for Asthma in Primary Care (Full Study) (PHASE4)
- Towards Digital Management of Paediatric Asthma (NA)
- Effects of Buteyko Breathing Exercise in Children With Uncontrolled Asthma (NA)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (PHASE4)
- Real World App-based CCAAP Management of Children With Asthma (NA)
- Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Asthma reliever and controller CI brief — competitive landscape report
- Asthma reliever and controller updates RSS · CI watch RSS
- Ivan Sofian Wibowo portfolio CI